AbbVie
Preço: 227.73Empresa e modelo de negócios
AbbVie is a global biopharmaceutical company focused on developing and delivering advanced therapies for complex diseases. Its core products include immunology, oncology, and neuroscience treatments, with key revenue sources stemming from blockbuster drugs such as Humira and newer therapies like Rinvoq and Skyrizi. The company operates primarily in the healthcare sector, emphasizing research and development to address unmet medical needs.
Perfil de investimento
AbbVie presents a balanced investment profile, appealing to investors seeking both growth and income through its solid dividend yield. The company's consistent revenue growth and established market presence suggest stability, while ongoing innovation in its product pipeline indicates potential for future expansion. This makes it suitable for investors with a medium to long-term horizon.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 2.04 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- -9.7% ↓
- Surpresa de EPS
- 2.3% em linha
- Volatilidade 20d
- 1.3% estável
- Dividend yield
- 3.7% moderado última data ex-dividendo: 2026-04-15
Impacto da previsão
negativoAcompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-01 02:55 | Comprar | Manter | Stable dividends, but mixed momentum and market signals. |
| 2026-05-24 02:30 | Manter | Comprar | Solid fundamentals, but mixed momentum signals. |
| 2026-05-08 15:02 | — | Manter | Weak momentum and high risk overshadow dividend appeal. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-05-15 12:20 | Evercore ISI | Preço-alvo reduzido | 236 → 235 | 212.045 |
| 2026-05-14 10:56 | Piper Sandler | Preço-alvo elevado | 294 → 298 | 208.5 |
| 2026-04-30 16:23 | Morgan Stanley | Preço-alvo elevado | 270 → 278 | 212.145 |
Nada ainda